- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| 29.07. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 09.07. | Roth/MKM initiates OS Therapies stock with buy on therapy outlook | 2 | Investing.com | ||
| 08.07. | OS Therapies: OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program | 512 | Newsfile | New York, New York and Rockville, Maryland--(Newsfile Corp. - July 8, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based... ► Artikel lesen | |
| 06.07. | OS Therapies: OS Therapies Third Quarter 2026 Corporate Outlook | 812 | Newsfile | New York, New York and Rockville, Maryland--(Newsfile Corp. - July 6, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based... ► Artikel lesen | |
| 02.07. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 02.07. | OS Therapies: OS Therapies Appoints Dr. Craig Eagle to Board of Directors | 976 | Newsfile | Company secures $10 million line of credit supported by OS Therapies UK tax creditsNew York, New York and Rockville, Maryland--(Newsfile Corp. - July 2, 2026) - OS Therapies, Inc. (NYSE American:... ► Artikel lesen | |
| 30.06. | OS Therapies: OS Therapies Provides U.S. Regulatory Update | 801 | Newsfile | Type B Meeting requested to follow up on September 2025 End of Phase 2 FDA Meeting guidance on statistical methods to be used for BLA SubmissionSeeking to align FDA with MHRA & EMA on 3-year overall... ► Artikel lesen | |
| 26.06. | OS Therapies: OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma | 642 | Newsfile | 20% of OST-HER2 treated dogs survived 2-year vs. 1% in control group (p = 0.00995)Over 15,000 dogs per year diagnosed with osteosarcomaCompany expects to submit U.S. Department of Agriculture meeting... ► Artikel lesen | |
| 08.06. | OS Therapies: OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma | 391 | Newsfile | Confirmatory Phase 3 trial to commence prior to BLA grant under Accelerated Approval Program in the U.S. and Conditional MAA in the U.K., Europe and AustraliaPatent pending pharmacodynamic response... ► Artikel lesen | |
| 02.06. | OS Therapies Says New Bone Cancer Data Strengthens Case For Regulatory Filings | 2 | Benzinga.com | ||
| 02.06. | OS Therapies: OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma | 834 | Newsfile | 75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no new patient deaths reported since the 2-year overall survival data (75% vs. 60%, p = 0.034)Updated... ► Artikel lesen | |
| 29.05. | OS Therapies: OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World | 583 | Newsfile | The Company confirms that it will release 2.5 year overall survival data from Phase 2b clinical trial OST-HER2 in the prevention or delay of recurrence in fully-resected pulmonary metastatic osteosarcoma... ► Artikel lesen | |
| 26.05. | OS Therapies: OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences | 549 | Newsfile | ASCO 2026: 2.5-Year Overall Survival DataJefferies Healthcare Conference: Partnering & Investor meetingsBIO International Convention: Panel ParticipationMIB Agents Factor Osteosarcoma Conference:... ► Artikel lesen | |
| 18.05. | OS Therapies GAAP EPS of -$0.27 | 1 | Seeking Alpha | ||
| 18.05. | OS Therapies: OS Therapies Reports First Quarter 2026 Financials and Provides Business Update | 739 | Newsfile | $5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027$4.5 million of accrued VAT refunds... ► Artikel lesen | |
| 18.05. | OS Therapies Inc - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.05. | OS Therapies: OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026 | 461 | Newsfile | New York, New York and Rockville, Maryland--(Newsfile Corp. - May 15, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based... ► Artikel lesen | |
| 14.05. | OS Therapies: OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor | 549 | Newsfile | Appointment strengthens medical, regulatory, and commercial leadership as Company prepares to complete early market access regulatory filings in the U.S., U.K, Europe and Australia in anticipation... ► Artikel lesen | |
| 12.05. | Reportable, Inc.: Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) | 469 | Newsfile | Dallas, Texas--(Newsfile Corp. - May 12, 2026) - OS Therapies Inc. (NYSE American: OSTX): Stonegate Capital Partners updates their coverage on OS Therapies Inc. (NYSE American: OSTX). OS Therapies... ► Artikel lesen | |
| 30.04. | OS Therapies Inc - 8-K, Current Report | - | SEC Filings |
1 2 3 4 Weiter >>
63 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 6,850 | -0,29 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 46,430 | +0,32 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 7,770 | 0,00 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 1,094 | -0,91 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,281 | +2,18 % | Der Weg zur Klinik: Wie Finanzierung Biotech-Erfolge ermöglicht | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,021 | -0,39 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,595 | +0,83 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| IMMUNIC | 13,180 | +6,59 % | EQS-News: Immunic AG: Immunic to Participate in Investor Conferences in July | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor Conferences in July
09.07.2026 / 12:30 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,050 | +0,96 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update | Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical toxicology, completion of Phase 1b pharmacology, and new IP announcementsKing... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,400 | -0,99 % | Onco-Innovations Limited: Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010's API | VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces the successful completion of its... ► Artikel lesen | |
| NOVOCURE | 13,700 | -3,32 % | Novocure Reports Second Quarter 2026 Financial Results | Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications
CE Mark received for Optune Paxfor the treatment of locally... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 7,700 | -3,14 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Second Quarter 2026 Financial Results and Business Highlights | Ocular's AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 3,140 | +0,32 % | Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial | ||
| ARCTURUS THERAPEUTICS | 7,395 | -0,20 % | Arcturus targets Q4 2026 Phase III decision for ARCT-032 as it regains global KOSTAIVE rights | ||
| PALISADE BIO | 2,110 | 0,00 % | Palisade Bio, Inc.: Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis | ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026... ► Artikel lesen |
Das Unternehmen OS THERAPIES INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,31 % bei einem Aktienkurs von 1,590 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.